Malad East, Mumbai, Maharashtra
Send E-mail
Send SMS

Pharmaceutical Injectables

Pharmaceutical Injectables, Cytarabine, or cytosine arabinoside, is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma.[1] It is also known as Ara-C (Arabinofuranosyl Cytidine).[2] It kills cancer cells by interfering with DNA synthesis.


Get Best Quote

Approx. Rs 500  / Piece(s) Get Latest Price

It is called Cytosine Arabinoside because it combines a cytosine base with an arabinose sugar. Cytosine normally combines with a different sugar, deoxyribose, to form deoxycytidine, a component of DNA. Certain , where it was originally found, use arabinoside sugars to form a different compound (not part of DNA). Cytosine arabinoside is similar enough to human cytosine deoxyribose (deoxycytidine) to be incorporated into human DNA, but different enough that it kills the cell. This mechanism is used to kill cancer cells. Cytarabine is the first of a series of cancer drugs that altered the sugar component of nucleosides. Other cancer drugs modify the base.

Yes! I am Interested
Ask Latest Price

Product Price: Get Latest Price

GemcitabineHCL is an anti-cancer chemotherapy drug and is classified as an antimetabolite. Gemcitabine is used to treat pancreas cancer, non-small cell lung cancer, bladder cancer, soft-tissue sarcoma, and metastatic breast cancer.

How to Use:

  • Gemzar is approved by the FDA in combination with carboplatin (another type of chemotherapy) for the patient with advanced ovarian cancer that has returned at least 6 months after the patient had finished platinum-based therapy
  • Gemzar is approved by the FDA in combination with cisplatin (another type of chemotherapy) for the first-line treatment of patients (for whom surgery is not possible) with locally advanced (stage IIIA or stage IIIB) or metastatic (stage IV or cancer that has spread) non-small cell lung cancer
  • Gemzar is approved by the FDA in combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after they have received another type of chemotherapy called an anthracycline, unless their medical condition did not allow them to receive an anthracycline
  • Gemzar is approved by the FDA as a single agent (given alone) as the first-line treatment for patients with locally advanced (stage II or stage III when surgery is not an option) or metastatic (stage IV) adenocarcinoma of the pancreas. Gemzar is also indicated for patients previously treated with 5-FU (another type of chemotherapy)


The most common side effects are low blood cell counts (red blood cells, white blood cells, and platelets); fever; infection; hair loss; tiredness; nausea; vomiting; constipation; diarrhea; rash; shortness of breath; muscle aches; blood in urine; hearing changes and numbness or tingling in your toes or fingers. Lab work may identify additional side effects.
Yes! I am Interested
Ask Latest Price

Product Price: Get Latest Price

We review the evidence of Botulinum Toxin in the treatment of pain. Main indications of botulinum toxin treatment, dystonia and spasticity, involve pain. Increasing evidence suggests direct analgesic effects of botulinum. Botulinum inhibits release of pain mediators (substance P, CGRP, excitatory amino acids, ATP, noradrenaline). Clinical trials have consistently shown analgesic effect of botulinum toxin in post-stroke shoulder pain, bladder dysfunction, chronic migraine, neuropathic pain, bruxism and lateral epicondylitis. Other pain conditions have been studied with yet uncertain results. It seems that the number of patients who would benefit from botulinum toxin treatment will increase considerably in the future.
Yes! I am Interested

Download Brochure
Explore more products
3s Corporation

Piyansh Mantry(CEO)
B/22 Padamnagar CHS, Andheri Kurla Road, Andheri East
Malad East, Mumbai - 400101
Maharashtra, India
Send Email
© 3s Corporation. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited